Susan Napier Thomas holds the Woodruff Professorship and is a Professor (full) with tenure of Mechanical Engineering in the Parker H. Petit Institute of Bioengineering and Bioscience at the Georgia Institute of Technology where she holds adjunct appointments in Biomedical Engineering and Biological Science and is a member of the Winship Cancer Institute of Emory University. Prior to this appointment, she was a Whitaker postdoctoral scholar at École Polytechnique Fédérale de Lausanne (one of the Swiss Federal Institutes of Technology) and received her B.S. in Chemical Engineering with an emphasis in Bioengineering cum laude from the University of California Los Angeles and her Ph.D. in Chemical & Biomolecular Engineering Department as a NSF Graduate Research Fellow from The Johns Hopkins University. For her contributions to the emerging field of immunoengineering, she has been honored with the 2022 Award for Young Investigator from Elsevier's journal Biomaterials for "outstanding contributions to the field" of biomaterials science, the 2018 Young Investigator Award from the Society for Biomaterials for "outstanding achievements in the field of biomaterials research" and the 2013 Rita Schaffer Young Investigator Award from the Biomedical Engineering Society "in recognition of high level of originality and ingenuity in a scientific work in biomedical engineering." Her interdisciplinary research program is supported by multiple awards on which she serves as PI from the National Cancer Institute, the Department of Defense, the National Science Foundation, and the Susan G. Komen Foundation, amongst others.

Dr. Arvanitis joined Georgia Institute of Technology as a joint Assistant Professor at the George W. Woodruff School of Mechanical Engineering and the Wallace H. Coulter Department of Biomedical Engineering in August 2016. Before joining Georgia Institute of Technology he was Instructor (Research Faculty) at Harvard Medical Scholl and Brigham and Women’s Hospital. Dr. Arvanitis has also worked as a research fellow in the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory at the Institute of Biomedical Engineering at the University of Oxford.

Dr. Varenberg’s research area is Tribology – the science and technology of interacting surfaces that allow for game-changing advancements ranging from making fire and inventing wheel in the past, to enabling human joint replacement in the present. Dr. Varenberg’s main focus is on bionic tribology and green tribology, but, to enhance the public’s interest in tribology science, he also seeks to uncover tribology from daily life, with examples of works on safety razors and table tennis paddles.

Dr. Yuhang Hu Joined the Woodruff School of Mechanical Engineering and the School of Chemical and Biomolecular Engineering at Georgia Institute of Technology as an assistant professor in August 2018. Prior to that, Dr. Hu was an assistant professor in the Department of Mechanical Science and Engineering at University of Illinois at Urbana-Champaign from 2015 to 2018. She received her Ph.D. from Harvard University in the area of Solid Mechanics. She worked in the area of Materials Chemistry as a post-doctoral fellow at Harvard from 2011 to 2014.

In the McCarty lab, we focus on the molecular physiology of ion channels and receptors, with emphasis on epithelial chloride channels. Our specific focus is the pathophysiology of Cystic Fibrosis, including the structure/function of CFTR and its many roles in the airway. We pioneered the use of peptide toxins as probes of chloride channels. We also have projects that study the functional consequences of heterodimerization among GPCRs, the role of CFTR in regulation of sweat composition, and the molecular ecology of predator-prey interactions in the marine environment. Our translational research in CF targets: (a) the mechanism by which the expression of mutant CFTR in airway epithelial cells impacts the development of CF-related diabetes; and (b) identification of biomarkers of acute pulmonary exacerbations in CF along with development of a novel device for their detection in the home. 

The goal of the Center for Cystic Fibrosis Research is to engage Atlanta researchers in basic and translational research that will lead to a better understanding of the pathophysiology of this disease and/or generate new devices and treatments to increase the length and quality of life for CF patients. The novel theme for these research activities is 'The Systems Biology of the CF Lung'.

Chunhui Xu, PhD, is a Professor in the Department of Pediatrics at Emory University School of Medicine and a member of the Cell and Molecular Biology Research Program at Winship Cancer Institute. 

Research in Dr. Xu's laboratory is focused on human cardiomyocytes derived from human pluripotent stem cells, which hold promise for cardiac cell therapy, disease modeling, drug discovery, and the study of developmental biology. They are also collaborating with investigators at Georgia Tech, Emory University, and Children's Healthcare of Atlanta, to explore the application of nanotechnology and tissue engineering in stem cell research.

The goal of Christopher Porter's lab is to develop novel therapeutic strategies for leukemia through better understanding of molecular mechanisms of leukemogenesis and treatment resistance. We employ a wide variety of techniques, in vitro and in vivo, for discovery and validation of molecular vulnerabilities in cancer cells. For example, using a genome-scale shRNA screen, we identified WEE1 as a chemosensitizing target in acute myeloid leukemia (AML) cells. Subsequent studies funded by the NCI have validated this finding and supported the development of a clinical trials a WEE1 inhibitor in subjects with AML. More recently, we have discovered a novel function for the transcription factor ETV6 in regulating normal hematopoiesis and are testing whether and how Etv6 mutation promotes leukemogenesis using a new mouse model with a point mutation in Etv6. Another project in the lab is directed at understanding mechanisms of immune evasion during leukemogenesis, as well as enhancing immune cells’ response to leukemia cells.

Peter Thule's research interests lie in the development of insulin gene therapy as a treatment for diabetes mellitus and investigations into hepatocellular effects of ectopic insulin production. His group's animal model utilizes a metabolically regulated, hepatic specific gene promoter to drive expression of an insulin transgene in the livers of diabetic rats. Administration of viral vectors containing these promoters coupled to a human insulin cDNA, normalizes blood sugars in diabetic rodents.

The Pacifici laboratory has pioneered the field of osteoimmunology and osteomicrobiology. The current main focus of the laboratory is the role of the microbiome in bone in health and disease. We are also interested in the mechanism of action of probiotics in bone. The laboratory is specialized in conducting in vivo studies in mice treated with PTH or subjected to ovariectomy. We use genetic models, retroviral transduction, bone marrow transplantation, T cell transfer and in vivo treatments with hormones, cytokines, antibodies and probiotics. Typical end points include sophisticated flow cytometric analysis of bone marrow cells and microCT and histomorphometric analysis of bone structure. The lab is equipped with in vivo and in vitro microCT scanners.

We have been the first to recognize that T cells play a pivotal role in the mechanism of action of estrogen and PTH in bone by regulating osteoclast and osteoblast development and function. More recently we have shown that the gut microbiome plays a role in mediating the skeletal response to estrogen deficiency and PTH. We have shown that mice lacking T cells are protected against the bone loss induced by estrogen deficiency and hyperparathyroidism. We have has also shown that T cells regulate the number and function of mesenchymal stem cells. We have investigated the mechanism by which T cells mediate the expansion of hemopoietic stem cells caused by estrogen deficiency and PTH. Another main focus is to understand why intermittent PTH treatment causes bone anabolism while continuous PTH treatment causes bone loss. We hypothesize that the response to PTH depends on the effects of this hormone on T cell production of Wnt10b and TNF. We are currently investigating the mechanism of action of probiotics in bone, and conducting a clinical trial to determine the efficacy of the probiotic VSL#3 in preventing postmenopausal bone loss.

The Pacifici laboratory is currently supported by 3 RO-1 grants, 1 DOD grant and a T32 grant.

The Yoon Lab has been working on stem cell research in various cardiovascular diseases. Our major research interest is to use stem cell technology to treat various cardiovascular diseases, and we have been developing and using different bone marrow-derived stem sell or progenitor cells for cardiovascular repair.